A detailed history of Advisors Asset Management, Inc. transactions in Vericel Corp stock. As of the latest transaction made, Advisors Asset Management, Inc. holds 16,890 shares of VCEL stock, worth $967,121. This represents 0.01% of its overall portfolio holdings.

Number of Shares
16,890
Previous 16,246 3.96%
Holding current value
$967,121
Previous $745,000 4.3%
% of portfolio
0.01%
Previous 0.01%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

BUY
$42.25 - $53.56 $27,209 - $34,492
644 Added 3.96%
16,890 $713,000
Q2 2024

Aug 14, 2024

SELL
$41.71 - $52.9 $10,928 - $13,859
-262 Reduced 1.59%
16,246 $745,000
Q1 2024

May 14, 2024

BUY
$32.52 - $52.33 $109,722 - $176,561
3,374 Added 25.69%
16,508 $858,000
Q4 2023

Feb 14, 2024

BUY
$30.85 - $37.09 $30,819 - $37,052
999 Added 8.23%
13,134 $467,000
Q2 2023

Aug 14, 2023

SELL
$29.0 - $38.37 $44,602 - $59,013
-1,538 Reduced 11.25%
12,135 $455,000
Q1 2023

May 12, 2023

BUY
$23.85 - $31.34 $21,154 - $27,798
887 Added 6.94%
13,673 $400,000
Q3 2022

Nov 08, 2022

BUY
$22.62 - $32.54 $10,224 - $14,708
452 Added 6.7%
7,197 $167,000
Q2 2022

Aug 08, 2022

BUY
$22.88 - $39.45 $48,368 - $83,397
2,114 Added 45.65%
6,745 $170,000
Q1 2022

May 17, 2022

SELL
$31.69 - $43.29 $27,506 - $37,575
-868 Reduced 15.78%
4,631 $177,000
Q4 2021

Feb 15, 2022

BUY
$35.2 - $52.6 $48,576 - $72,588
1,380 Added 33.5%
5,499 $216,000
Q3 2021

Nov 12, 2021

BUY
$46.35 - $59.75 $58,864 - $75,882
1,270 Added 44.58%
4,119 $201,000
Q2 2021

Jul 30, 2021

BUY
$47.2 - $67.81 $134,472 - $193,190
2,849 New
2,849 $150,000

Others Institutions Holding VCEL

About Vericel Corp


  • Ticker VCEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 47,178,000
  • Market Cap $2.7B
  • Description
  • Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for t...
More about VCEL
Track This Portfolio

Track Advisors Asset Management, Inc. Portfolio

Follow Advisors Asset Management, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Advisors Asset Management, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Advisors Asset Management, Inc. with notifications on news.